Financial Performance - Third-quarter 2025 revenues totaled $16.7 billion, a decrease of 6% year-over-year, reflecting an operational decline of 7%[4] - Reported diluted EPS for the third quarter was $0.62, down 21% from the prior year, while adjusted diluted EPS was $0.87, also down 18%[4] - Product revenues for Q3 2025 were $13.92 billion, a decrease of 10% compared to $15.42 billion in Q3 2024[34] - Total revenues for the first nine months of 2025 were $45.02 billion, down 2% from $45.86 billion in the same period of 2024[34] - Net income attributable to Pfizer Inc. common shareholders for Q3 2025 was $3.54 billion, a decrease of 21% from $4.47 billion in Q3 2024[34] - Total revenues for 2025 were $16,654 million, a decrease of 6% compared to $17,702 million in 2024[53] - The Global Biopharmaceuticals business generated $16,310 million in 2025, down 6% from $17,392 million in 2024[53] - Total revenues for 2025 were $45,022 million, a decrease of 2% compared to $45,864 million in 2024[55] - The Global Biopharmaceuticals business generated $44,056 million in 2025, down 2% from $44,987 million in 2024[55] Guidance and Projections - The company reaffirms full-year 2025 revenue guidance in the range of $61.0 to $64.0 billion[4] - Adjusted diluted EPS guidance for 2025 has been raised and narrowed to a range of $3.00 to $3.15, up from the previous range of $2.90 to $3.10[9] - Pfizer expects an unfavorable revenue impact of approximately $0.4 billion due to generic and biosimilar competition for certain products[31] - The company is on track to deliver approximately $7.7 billion in anticipated overall savings from cost improvement initiatives[32] - Pfizer's ongoing cost realignment program is expected to achieve approximately $4.5 billion in net cost savings by the end of 2025[32] Research and Development - The company invested approximately $7.2 billion in internal R&D projects and $1.6 billion in business development transactions during the first nine months of 2025[11] - Pfizer's development pipeline includes a comprehensive update available on their website, detailing compounds in various phases of development[25] - In the Phase 2 PHAROS trial, Braftovi + Mektovi showed a median overall survival of 47.6 months for treatment-naïve patients after a median follow-up of 52.3 months[20] - The Phase 3 clinical trial of the LP.8.1-adapted Comirnaty COVID-19 vaccine demonstrated a robust increase in neutralizing antibodies in adults aged 65 and older[22] - The Phase 3 EV-303 trial for Padcev showed a 60% reduction in the risk of tumor recurrence or death compared to surgery alone, with an estimated 74.7% event-free rate at two years[23] - Xtandi plus leuprolide reduced the risk of death by 40.3% in men with non-metastatic hormone-sensitive prostate cancer, with an 8-year overall survival of 78.9%[24] - Inclacumab did not meet its primary endpoint in the Phase 3 THRIVE-131 study for sickle cell disease, although it was generally well tolerated[26] Acquisitions and Strategic Initiatives - Pfizer secured early FTC clearance for the proposed Metsera acquisition, aimed at enhancing competition in the obesity market[3] - Pfizer has entered into a definitive agreement to acquire Metsera for $4.9 billion, with potential additional payments of up to $22.50 per share tied to specific milestones[27] - The U.S. Federal Trade Commission granted early termination of the waiting period for Pfizer's acquisition of Metsera, obtaining all required regulatory approvals[27] - The company is confident in the merits of its lawsuits against Metsera and Novo Nordisk regarding a competing acquisition proposal[27] Cost Management and Expenses - Pfizer is on track to deliver approximately $7.2 billion in anticipated net cost savings from previously announced cost improvement initiatives by the end of 2027[4] - Adjusted cost of sales for Q3 2025 was $3,979 million, an 18% decrease from $4,874 million in Q3 2024, representing 23.9% of revenues[19] - Adjusted R&D expenses for the first nine months of 2025 were $7,096 million, down 8% from $7,708 million in the same period of 2024[19] - Restructuring charges for the third quarter of 2025 totaled $286 million, compared to $313 million in the same period of 2024, with total charges for the first nine months of 2025 amounting to $945 million, down from $1.669 billion in 2024[37] - Net interest expense decreased to $514 million in the third quarter of 2025 from $668 million in 2024, with total interest expense for the first nine months of 2025 at $1.523 billion, down from $1.977 billion in 2024[38] Market Challenges and Risks - The company is facing risks related to the proposed acquisition of Metsera, including competition from Novo Nordisk's proposal and uncertainties in closing the transaction[62] - The company reported challenges in marketing existing products and potential delays in manufacturing and sales due to supply chain disruptions[62] - The impact of COVID-19 on the company's financial condition remains uncertain, with potential reduced demand for COVID-19 products leading to decreased revenues[62] - The company is navigating risks associated with tariffs, geopolitical instability, and climate change disruptions that could affect operations[64] - The company is evaluating its product portfolio for potential risks related to nitrosamines, which may impact product recalls and regulatory assessments[64] - The company is facing uncertainties regarding the approval and commercialization of new product candidates, which may require additional clinical data[67] - The company is exposed to risks related to intellectual property, including potential patent challenges and cybersecurity threats[69] Taxation and Financial Metrics - Pfizer's effective tax rate on reported income for Q3 2025 decreased to 7.9% from 10.8% in Q3 2024, primarily due to favorable changes in earnings jurisdiction and tax benefits[19] - The effective tax rates for income from continuing operations were (6.5)% for the third quarter of 2025, compared to 5.0% in 2024, primarily due to a favorable change in the jurisdictional mix of earnings[41] - Adjusted income is used by management to evaluate overall performance, excluding certain items such as amortization of intangible assets and acquisition-related costs[43] - The company aims to enhance investor understanding of performance through the disclosure of adjusted income and adjusted diluted EPS as non-GAAP financial measures[43] Shareholder Returns - Total shareholder return is a significant factor in determining payouts under the company's incentive compensation plans[44] - Non-GAAP adjusted net income for Third-Quarter 2025 was $4,949 million, resulting in diluted earnings per share of $0.87[46] - For the nine months ended September 28, 2025, GAAP reported net income was $2,210 million, with diluted earnings per share of $1.65[46] - Non-GAAP adjusted net income for the nine months ended September 28, 2025 was $14,620 million, leading to diluted earnings per share of $2.56[46]

Core Insights - Pfizer reported third-quarter earnings and revenue that exceeded estimates, raising its full-year profit guidance due to cost-cutting measures offsetting declining sales [1] - The company became the first drugmaker to agree to sell medications at lower prices under a deal with President Trump, linking U.S. drug prices to those abroad [1] - Pfizer plans to invest $70 billion in U.S. manufacturing and research facilities as part of a three-year grace period to avoid pharmaceutical-specific tariffs [2] Financial Performance - Adjusted earnings per share were reported at 87 cents, surpassing the expected 63 cents [4] - Revenue for the quarter was $16.65 billion, slightly above the expected $16.58 billion [4] Competitive Landscape - Pfizer is engaged in a bidding war with Novo Nordisk for the acquisition of obesity biotech Metsera, filing a lawsuit against Novo Nordisk for alleged anticompetitive practices [3]

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity start up Metsera https://t.co/6r3l2S0rNT ...

Core Viewpoint - Pfizer reported an adjusted earnings per share of $0.87 for the third quarter and maintains its full-year revenue forecast of $61 billion to $64 billion [1] - The company has raised its full-year adjusted earnings per share guidance to $3.00 to $3.15, up from the previous estimate of $2.90 to $3.10 [1] - Following the earnings report, Pfizer's stock rose over 2% in pre-market trading [1] Financial Performance - Adjusted earnings per share for Q3 stood at $0.87 [1] - Full-year revenue forecast is set between $61 billion and $64 billion [1] - Adjusted earnings per share guidance for the full year has been increased to a range of $3.00 to $3.15 [1]

Core Insights - Pfizer raised its full-year profit forecast for the second consecutive time, driven by robust demand for its leading heart treatment and blood thinner [1] Company Summary - Pfizer's updated profit forecast reflects strong market performance and increased sales of its key pharmaceutical products [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Pfizer reported solid third-quarter 2025 results, reaffirming its revenue guidance while raising and narrowing its adjusted diluted EPS guidance for the year [1][7][12] Financial Performance - Third-quarter 2025 revenues totaled $16.7 billion, a decrease of 6% year-over-year, with an operational decline of 7% [5][15] - Reported net income for the third quarter was $3.54 billion, down 21% from $4.47 billion in the prior year [5] - Reported diluted EPS was $0.62, a decrease of 21% compared to $0.78 in the same quarter last year [5] - Adjusted diluted EPS for the third quarter was $0.87, down 18% from $1.06 in the prior year [8] Revenue Breakdown - The biopharmaceutical segment generated $16.31 billion in revenues, a 6% decline year-over-year [9] - Significant declines were noted in COVID-19 product revenues, particularly Paxlovid and Comirnaty, due to lower infection rates and a narrower vaccination recommendation [17][15] - Non-COVID portfolio showed a 4% operational revenue growth, indicating strengthened commercial execution [7] Guidance and Cost Management - Pfizer reaffirmed its full-year 2025 revenue guidance in the range of $61.0 to $64.0 billion [11] - Adjusted diluted EPS guidance was raised to a range of $3.00 to $3.15, reflecting confidence in business performance and cost improvement initiatives [12][11] - The company is on track to deliver approximately $7.2 billion in net cost savings from previously announced cost improvement initiatives by the end of 2027 [7][42] Strategic Developments - Pfizer reached a landmark agreement with the U.S. Government to ensure drug pricing parity with other developed countries, enhancing business clarity [2][31] - The company secured early FTC clearance for the proposed acquisition of Metsera, aimed at competing in the obesity market [6][32] - Pfizer is involved in legal actions against Metsera and Novo Nordisk regarding a competing acquisition proposal, seeking to enforce the merger agreement [33][35] Recent Product Developments - Positive results were announced for several ongoing clinical trials, including the Phase 3 trial for Comirnaty and the Phase 2 trial for Braftovi + Mektovi [25][28] - The company continues to invest in its pipeline, with a comprehensive update available on its website [28]

U.S. stock futures were in the red with earnings due later from Advanced Micro Devices, Uber, Pfizer and Thomson Reuters. ...

Core Viewpoint - Pfizer has filed a second lawsuit against Novo Nordisk, accusing it of anti-competitive behavior in its attempt to acquire weight-loss drug manufacturer Metsera, claiming that the bid is aimed at maintaining market share rather than genuine acquisition interests [2][6]. Group 1: Legal Actions and Accusations - Pfizer has submitted a lawsuit to the U.S. District Court in Delaware, alleging that Metsera's controlling shareholders colluded with Novo Nordisk to influence the development of new drugs [3]. - Pfizer has requested a temporary restraining order to prevent Metsera from terminating its agreement with Pfizer [5]. - The lawsuit claims that Novo Nordisk offered $6.5 billion in prepayment to Metsera's shareholders before regulatory review, including restrictive clauses that could delay or obstruct new drug clinical progress [7]. Group 2: Market Dynamics and Competitive Landscape - The ongoing legal battle highlights the intense competition between Pfizer and Novo Nordisk over Metsera, which has a promising weight-loss drug pipeline projected to generate $5 billion in annual revenue [10]. - Metsera has received seven acquisition offers this year, with Novo Nordisk's final bid valuing the company at $9 billion, exceeding Pfizer's offer by over $1 billion [10]. - Novo Nordisk's market dominance in weight-loss drugs is under threat, especially with the expiration of its core product GLP-1 drug semaglutide's patent in China by 2026, which is expected to lead to the entry of numerous generics [10]. Group 3: Industry Trends and Competitor Performance - The weight-loss drug market is seeing significant investments from major players like Novo Nordisk and Eli Lilly, with Eli Lilly currently outperforming Novo Nordisk in recent data, leading to a nearly 40% drop in Novo Nordisk's stock price this year [11]. - Eli Lilly's GLP-1 drug tirzepatide generated $24.837 billion in revenue in the first three quarters, surpassing Merck's blockbuster cancer drug Keytruda [11]. - Other competitors in the weight-loss drug sector include Roche, Amgen, AstraZeneca, and Merck, all of which are entering the market through self-research and acquisition strategies [11]. Group 4: Emerging Players in China - In the Chinese market, Innovent Biologics' weight-loss drug product, mazhidutide, is in the early stages of growth, with several other companies like Heng Rui Medicine, Shijiazhuang Pharmaceutical Group, and East China Pharmaceutical actively investing in this field [12].

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the year-ago period. The consensus estimate for Pfizer’s quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier, according to Benzinga Pro.On Friday, Pfizer filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk ( ...